BioSpace News Archive

The Global Smart Inhalers Market is expected to reach US$ 8,033.21 Mn in 2027 from US$ 1,094.26 Mn in 2018.

Results from two large clinical trials show significant and early benefits from sotagliflozin, a drug that inhibits sodium-glucose transport protein 2 and sodium-glucose transport protein 1 in reducing heart failure, heart attack, and stroke—major problems in people with diabetes.

OmniVision Technologies, Inc., a leading developer of advanced digital imaging solutions, today announced its next-generation OH08A and OH08B CMOS image sensors―the first 8 megapixel (MP) resolution sensors for single-use and reusable endoscopes.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical data for LN-145 TIL therapy in non-small cell lung cancer today at 4:30 p.m. ET.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the first quarter of 2021.

Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced additional results from a Phase 1 study in healthy volunteers of VE202, the Company’s 16-strain live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD).

AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced that as part of the annual reconstitution of the Russell stock indexes, AVITA Medical has been added to the Russell 3000® Index effective June 28, 2021.

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), today provided a corporate update and reported financial results for its fiscal year ended March 31, 2021.

Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced information regarding a key supply chain insight for OC-01 (varenicline) nasal spray following the announcement that an unrelated manufacturer of varenicline oral tablets has suspended distribution due to impurities discovered in one or more lots of its product.

N2 Biomedical, a leading provider of coating and surface treatment solutions to the medical device industry, is pleased to announce that Keith Edwards has been appointed Chief Executive Officer.